Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug;17(4):322-8.
doi: 10.1097/MED.0b013e32833ada91.

New technologies for autoimmune disease monitoring

Affiliations
Review

New technologies for autoimmune disease monitoring

Holden T Maecker et al. Curr Opin Endocrinol Diabetes Obes. 2010 Aug.

Abstract

Purpose of review: This article will review new technologies used to characterize the immune phenotype of cells and serum for potential use in studies of autoimmunity.

Recent findings: One area of recent development in studies of immune phenotyping is the contrast between cells of the immune system at rest and following activation. This simply involves comparing these cells at rest and following ligand-induced activation and measuring signaling system activation (phosphoepitope identification) or intracellular cytokine production or activation-induced gene expression. Preliminary data using these techniques have begun to identify signatures of disease (biomarkers) that are only seen when using these activation-induced assays. One of the most exciting new technologies, cytometry by time-of-flight mass spectrometry, couples a flow cytometer to a mass spectrometer, allowing many more parameters to be analyzed per cell, and without spillover between assay reagents, compared to conventional optical flow cytometry (heavy ions, mass, replaces fluorophore readout). Another new technology to analyze soluble proteins, bead-based immunoassays, can simultaneously measure up to 75 soluble analytes in a multiplexed array. Other technologies provide similar innovations in terms of analytical content, throughput, and miniaturization.

Summary: We believe that new cellular genomic and protein-based technologies can provide key insights into autoimmune disease pathogenesis, progression, and therapy, and that these assays need to be applied in a systematic way to samples from patients with autoimmune diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cytometry by time-of-flight mass spectrometry principle
(a) Principle of cytometry by time-of-flight mass spectrometry: antibody labeling with heavy metal isotopes, binding of labeled antibodies to cells, and conversion of labeled cells to plasma for quantitation of heavy isotopes by time-of-flight mass spectrometry. (b) Limitation of the visible spectrum is shown by the overlap in emission spectra of eight common fluorescent dyes. (c) By contrast, elemental isotopes of different mass are exquisitely separated by time-of-flight mass spectrometry, allowing many more labeled antibodies to be combined, without interference between labels.

References

    1. Butterfield LH, Disis ML, Fox BA, et al. A systematic approach to biomarker discovery; Preamble to ‘the iSBTc-FDA taskforce on Immunotherapy Biomarkers’. J Transl Med. 2008;6:81. - PMC - PubMed
    1. Kodama K, Butte AJ, Creusot RJ, et al. Tissue- and age-specific changes in gene expression during disease induction and progression in NOD mice. Clin Immunol. 2008;129:195–201. Whole genome oligo-microarrays were used to characterize age-dependent and tissue-specific changes in gene expression in pancreatic lymph nodes, spleen, and peripheral blood cells, obtained from up to eight individual NOD mice at six different time points (1.5–20 weeks of age), compared to NOD.B10 tissue controls. These studies identified tissue-specific and age-specific changes in gene expression that may play an important role in the inductive or destructive events of T1D. - PMC - PubMed
    1. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731–2738. - PubMed
    1. Davis MM. A prescription for human immunology. Immunity. 2008;29:835–838. - PMC - PubMed
    1. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 2004;118:217–228. - PubMed

Publication types